可手术切除的局部进展期非小细胞肺癌患者新辅助治疗研究进展  

Progress of Neoadjuvant Therapy for Resectable Locally Advanced Non-small Cell Lung Cancer

作　　者：杨森 谢颂平[1] 黄杰[1] YANG Sen;XIE Songping;HUANG Jie(Thoracic Surgery,Renmin Hospital of Wuhan University,Wuhan 430060,China)

机构地区：[1]武汉大学人民医院胸外科,湖北省武汉市430060

出　　处：《实用心脑肺血管病杂志》2022年第3期131-136,共6页Practical Journal of Cardiac Cerebral Pneumal and Vascular Disease

摘　　要：肺癌是全球范围内发病率和死亡率最高的恶性肿瘤。对于可手术切除的局部进展期非小细胞肺癌(NSCLC)患者,当前国内外相关指南建议采取多模式联合治疗,包括手术、放化疗、靶向治疗及免疫治疗等。术前新辅助治疗指在恶性肿瘤手术切除前给予化疗或放疗,近年随着靶向药物与免疫检查点抑制剂(ICI)的快速发展,新辅助治疗又延伸出新辅助靶向治疗及新辅助免疫治疗。本文主要综述了可手术切除的局部进展期NSCLC患者新辅助治疗进展,以提高临床医生对肺癌新辅助治疗的认识。Lung cancer is the malignant tumor with the highest morbidity and mortality in the world.For patients with resectable locally advanced non-small cell lung cancer(NSCLC),the current treatment guidelines at home and abroad recommend combined multimode therapy,including surgery,radiotherapy and chemotherapy,targeted therapy and immunotherapy.Neoadjuvant therapy refers to chemotherapy or radiotherapy before surgical resection of malignant tumors.With the rapid development of targeted drugs and immune checkpoint inhibitors(ICI),neoadjuvant therapy also extends neoadjuvant targeted therapy and neoadjuvant immunotherapy.This article mainly reviews the progress of neoadjuvant therapy in patients with resectable locally advanced NSCLC,in order to improve clinicians'understanding of neoadjuvant therapy for lung cancer.

关 键 词：非小细胞肺癌 新辅助治疗 放化疗 靶向治疗 免疫治疗 综述 

分 类 号：R730.26[医药卫生—肿瘤]